Drugs / Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03691376 | Mar 2019 → Jan 2021 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT03450122 | Sep 2018 → Dec 2022 | myxoid liposarcoma, synovial sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02319824 | Jan → Jun 2015 | sarcoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02059850 | Jul 2014 → Jan 2016 | myxoid/round cell liposarcoma, synovial sarcoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous NY-ESO-1-specific CD8-positive T Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03691376 ↗ |
| Known as | NY-ESO-1 specific T cells | “This phase I trial studies the side effects and best way to give NY-ESO-1 specific T cells after cyclophosphamide in treating patients with advanced synovial sarcoma or...” NCT02059850 ↗ |
| Action | Deplete | “kill tumor cells that express NY-ESO-1” NCT02319824 ↗ |
| Modality | Cell therapy | “Autologous NY-ESO-1-specific CD8-positive T Lymphocytes” NCT02059850 ↗ |
| Route | Intravenous | “Given IV” NCT02059850 ↗ |